Pancreatic Cancer Research

ResearcherAalborg University HospitalActive in the last 2 years

Ole Thorlacius‐Ussing

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4963-1551; OpenAlex author ID A5082379448. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 5 papers · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 17

  1. Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2025.1568386↗
  2. Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients. Co-author DOI 10.1016/j.isci.2024.111026↗
  3. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocar… Last author DOI 10.1016/j.pan.2023.05.003↗
  4. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1211292↗
  5. Irreversible electroporation of pancreatic cancer - Effect on quality of life and pain perception. Last author DOI 10.1016/j.pan.2021.04.011↗
  6. Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma - An external validation study. Last author DOI 10.1016/j.pan.2021.05.003↗
  7. Usefulness of Imaging Response Assessment after Irreversible Electroporation of Localized Pancreatic Cancer-Results from a Prospective Cohort. Co-author DOI 10.3390/cancers13122862↗
  8. Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic … Last author DOI 10.3390/cancers13225717↗
  9. Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma-A Literature Update. First author DOI 10.3390/epigenomes5020008↗
  10. Imaging response evaluation after local ablative treatments in locally advanced pancreatic cancer: an expedited systematic review. Co-author DOI 10.1016/j.hpb.2020.04.011↗
  11. MicroRNAs and Neutrophil Activation Markers Predict Venous Thrombosis in Pancreatic Ductal Adenocarcinoma and Distal Extrahepatic Cholangiocarcinoma. Co-author DOI 10.3390/ijms21030840↗
  12. Treatment of locally advanced pancreatic cancer with irreversible electroporation - a Danish single center study of safety and feasibility. Last author DOI 10.1080/00365521.2019.1575465↗
  13. Promoter hypermethylation in plasma-derived cell-free DNA as a prognostic marker for pancreatic adenocarcinoma staging. Last author DOI 10.1002/ijc.31024↗
  14. Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma. Last author DOI 10.18632/oncotarget.21397↗
  15. D-Dimer predicts prognosis and non-resectability in patients with pancreatic cancer: a prospective cohort study. Last author DOI 10.1097/mbc.0000000000000559↗
  16. Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma. Last author DOI 10.1186/s13148-016-0286-2↗
  17. DNA Hypermethylation as a Blood-Based Marker for Pancreatic Cancer: A Literature Review. Last author DOI 10.1097/mpa.0000000000000487↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stine Dam Henriksen · 11 shared papers, 2015–2025 · strength 1.48
  2. Mogens Tornby Stender · 6 shared papers, 2016–2024 · strength 0.86
  3. Benjamin Emil Stubbe · 5 shared papers, 2021–2025 · strength 0.81
  4. Rasmus Virenfeldt Flak · 5 shared papers, 2019–2024 · strength 0.77
  5. Julia Sidenius Johansen · 4 shared papers, 2021–2025 · strength 0.67
  6. Carsten Palnæs Hansen · 4 shared papers, 2021–2025 · strength 0.67
  7. Astrid Zedlitz Johansen · 2 shared papers, 2023–2025 · strength 0.36
  8. Lars Jelstrup Petersen · 2 shared papers, 2020–2021 · strength 0.30
  9. Susy Shim · 1 shared paper, 2024 · strength 0.20
  10. Morten Bækbo Ladekarl · 1 shared paper, 2024 · strength 0.20
  11. Sönke Detlefsen · 1 shared paper, 2024 · strength 0.20
  12. Lars Henrik Jensen · 1 shared paper, 2025 · strength 0.19
  13. Louise S. Rasmussen · 1 shared paper, 2025 · strength 0.19
  14. Per Pfeiffer · 1 shared paper, 2025 · strength 0.19
  15. Inna Markovna Chen · 1 shared paper, 2025 · strength 0.19
  16. Pilar Medina · 1 shared paper, 2020 · strength 0.11
  17. Júlia Oto · 1 shared paper, 2020 · strength 0.11
  18. Asbjørn Mohr Drewes · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.